Murine neurovirulence studies with a chimeric poliovirus: in vivo generation of a mutant base-paired stable attenuated poliovirus.
We investigated the neurovirulence of a chimeric poliovirus consisting of the coding region of Lansing type 2 poliovirus and the 5'NCR of type 3 poliovirus. Specifically we carried out studies on the effects of stable base pairing, between nucleotides 472 and 537, on neurovirulence. Mice were injected intracranially with the attenuated chimeric virus MAS 27 plaque 1 having the following nucleotide base pair at 472-537, G-G. Mutants recovered from the CNS of inoculated mice were divided into three groups according to the nucleotide sequence of the 5'NCR; MAS 27C type viruses having a single base change (G-C) at the position 472, MAS 27G type mutants having a single base change (G-C) at the position 537, and MAS 27U type viruses having a single base change (G-U) at the position 537. The isolate MAS 27C had back-mutated to the wild type, and 100 000 fold more virulent than attenuated MAS 27G and MAS 27U. MAS 27C type mutants were predominant, suggesting that base C at position 472 is favoured to form a stable secondary structure with guanine at position 537. Attenuated MAS 27G, however, carries guanine and cytosine at nucleotides 472 and 537 respectively, and was a stable attenuated virus following passage in four serial generations of mice. Furthermore, attenuated MAS 27G poliovirus produced viral proteins less efficiently and had slower growth rates than the revertant MAS 27C. The stable attenuated base paired MAS 27G might provide the basis for a prototype for a live attenuated stable type 3 poliovaccine.
Lee
C
C
College of Veterinary Medicine, Texas A&M University, College Station, Texas, 77843-4467, U.S.A.
Young
C
C
D000818:Animals; D001483:Base Sequence; D001921:Brain / Q000821:virology; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics*; D017955:Poliovirus / Q000276:immunology* / Q000472:pathogenicity; D011054:Poliovirus Vaccine, Inactivated / Q000235:genetics*; D012367:RNA, Viral / Q000032:analysis; D014613:Vaccines, Attenuated / Q000235:genetics; D010948:Viral Plaque Assay; D014774:Virulence
D011054:Poliovirus Vaccine, Inactivated; D012367:RNA, Viral; D014613:Vaccines, Attenuated